1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Alzheimer’s Drugs Market, 2012 - 2017

  • May 2013
  • 117 pages
  • Roots Analysis Private Ltd.
Report ID: 1364216


Table of Contents

Search Inside

Alzheimer’s disease is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. With ageing world population, the number of patients suffering from Alzheimer’s disease is expected to increase in the future. There is a huge unmet need in the market owing to lack of effective, disease-modifying drugs.

Alzheimer’s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patents of leading drugs have either expired or are close to expiry. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity.

The pipeline for Alzheimer’s drugs is rich, with drug developers looking for drugs with disease-modifying ability rather than just symptomatic treatments. However, the recent failure of several Alzheimer’s drugs in late stage clinical trials present the challenges of developing disease-modifying drugs for areas with an unknown cause. The uncertainty related to the cause of disease, along with unexpected side effects of drugs due to differential responses by individual brains, pose major challenges for drug developers.

Amongst other things, this report provides a detailed overview of the most promising pipeline drugs for the treatment of Alzheimer’s. The market is desperate for a therapy that can slow or reverse disease progression. The next five years, from 2012-2017, will see the launch of many new drugs.

Scope of the Report
The Alzheimer’s drug market (2012-2017) report extensively examines the various aspects of the disease’s development, commercial and pipeline drugs, associated challenges and initiatives taken by various countries to tackle the disease’s spread and raise consumer awareness.

The report focuses on both the regional and global trends centred around drug use and development in the following two key segments:
- Acetylcholinesterase inhibitors and
- NMDA receptor antagonists

A key objective of the report is to establish the likely evolution of leading drugs, generics and launch of new drugs across the different regions in the world. The report discusses various historical / future trends which have shaped / will shape the US, European and Japanese markets. The research, analysis and insights presented in this report do not include the sales of any diagnostic tests or radiopharmaceuticals available in the market for Alzheimer’s diagnosis.

The market forecasts across different segments, regions, brands have been presented till 2017. 2011 is the base year and actual figures have been taken, analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the pipeline drugs in various stages of clinical trials.

Key Highlights
1. The World Alzheimer Report estimates that 35.6 MM people worldwide were living with dementia in 2010. It is estimated that this number will nearly double to 65.7 MM by 2030 and to 115.4 MM by 2050. The occurrence is highest in Asian countries.
2. The market is categorised under two segments, namely, Acetylcholinesterase inhibitors and NMDA receptor antagonists. Acetylcholinesterase (AChE) Inhibitors dominate the market with net worth equal to USD 4,158 MM in 2011.
3. The overall market is dominated by four leading brands – Aricept, Namenda, Exelon and Ebixa. Aricept, whose active ingredient is an AChE inhibitor, accounted for over 40% of the total market in 2011
4. The US was the largest market for Alzheimer’s drugs in 2011 with and accounted for 34.5% of the total market in 2011.
5. With the expiry of patents of branded drugs, new generics have already entered the market
6. With all the existing drugs being symptomatic, a number of companies are competing to bring a breakthrough therapy in the market. There are several drugs which are in Phase I, II or III clinical trials.
7. Opportunities in the market outpace the threats. Increasing prevalence of the disease and an ageing population will add to the disease burden in the coming years.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.